Cytokine

Schrödinger Presents Data Supporting Advancement of SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting

Retrieved on: 
Sunday, December 10, 2023

The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.

Key Points: 
  • The preclinical data reported show that both SGR-1505 and SGR-2921 have multiple favorable attributes and the potential for combination activity with standard-of-care agents.
  • The company will report additional data from the healthy subject study at its Pipeline Day on December 14, 2023.
  • “The pharmacological data for SGR-1505 and SGR-2921 demonstrate that our development candidates have favorable, differentiated profiles with best-in-class potential,” stated Karen Akinsanya, Ph.D., president of R&D therapeutics at Schrödinger.
  • “Our progress within these programs further validates our computational approach to designing therapies with the potential to address the limitations of current treatments.

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

Retrieved on: 
Tuesday, December 5, 2023

Takeda ( TSE:4502/NYSE:TAK ) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) and The New York Academy of Sciences today announced the winners of the 2024 Innovators in Science Award for their excellence in, and commitment to, innovative science that has significantly advanced the field of research in cancer immunology.
  • “The Innovators in Science Award motivates me, my team and the broader community to continue on the path of blending multiple fields to find creative cancer immunology solutions.
  • “The 2024 Innovators in Science Award winners are using AI, computational tools and groundbreaking methods to fight cancer and advance the field of cancer immunology.
  • We congratulate the winners and eagerly await their future discoveries.”
    The 2024 winners will be honored at the Innovators in Science Award ceremony and symposium in April 2024 in Boston.

COVID-19’s impact on the vagus nerve, inflammatory reflex & long COVID: Feinstein Institutes & Karolinska Institutet study outlines potential therapies

Retrieved on: 
Wednesday, November 29, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231129335345/en/
    Dr. Kevin J. Tracey co-authored a new paper on the relationship between SARS-CoV-2 and the vagus nerve.
  • They also discussed potential therapies, particularly to reduce the progression of COVID-19 in infected patients as well as long COVID-19 treatment options.
  • “Studying the connection between COVID-19 and the vagus nerve is an important research avenue that needs further study,” said Dr. Andersson.
  • At the Feinstein Institutes, medical researchers use modern technology to develop new device-based therapies to treat disease and injury.

Research-grade Proteins (Cytokines & Growth Factors, Antibodies) Market Size, Share & Trends Analysis Report 2023 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 29, 2023

The "Research-grade Proteins Market Size, Share & Trends Analysis Report By Product (Cytokines & Growth Factors, Antibodies), By Host Cell (Mammalian Cells, Bacterial Cells), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research-grade Proteins Market Size, Share & Trends Analysis Report By Product (Cytokines & Growth Factors, Antibodies), By Host Cell (Mammalian Cells, Bacterial Cells), By End-use, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global research-grade proteins market size is estimated to reach USD 2.69 billion by 2030, growing at a CAGR of 15.53% from 2023 to 2030.
  • In addition, the rising government investments in numerous countries for various clinical studies are expected to drive the growth of the market.
  • Moreover, the growing advancements in the biotechnology industry in developing countries are further driving the growth of the market over the forecast period.

Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference

Retrieved on: 
Tuesday, November 21, 2023

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023, at 8:00 a.m.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that company management will present at the Piper Sandler 35th Annual Healthcare Conference in New York City on Tuesday, November 28, 2023, at 8:00 a.m.
  • ET / 11:00 a.m. PT.
  • A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com .
  • After the webcast, a replay will be archived on the website for at least 30 days.

Reverb Therapeutics Debuts Its Amplifier™ Platform for Redirecting Endogenous Cytokines 

Retrieved on: 
Wednesday, November 15, 2023

Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .

Key Points: 
  • Reverb Therapeutics, a leader in the emerging paradigm of redirecting endogenous cytokines as treatments for life-threatening diseases, debuts with seed financing led by founding investor Amplitude Ventures and participation from the Multiple Myeloma Research Foundation’s venture philanthropy arm, the Myeloma Investment Fund .
  • Reverb Therapeutics is advancing its novel antibody-based AmplifierTM platform to treat a broad range of diseases with endogenous cytokines that naturally occur within the body.
  • Instead of using heavily engineered exogenous cytokines to treat disease—which have consistently presented challenges such as systemic toxicity, immunogenicity and challenging production requirements—Reverb’s antibodies redirect endogenous, natural cytokines to cells of interest.
  • “We are keenly aware of the clinical obstacles to more widespread use of exogenous cytokines to treat patients,” said David de Graaf, Ph.D., Co-founder and CEO of Reverb Therapeutics.

Orionis Biosciences Announces First Patient Dosed in Phase 1 Clinical Trial of ORB-011 in Patients with Advanced Solid Tumors

Retrieved on: 
Wednesday, November 15, 2023

The company is also announcing the appointment of Tony Fadell to its Board of Directors.

Key Points: 
  • The company is also announcing the appointment of Tony Fadell to its Board of Directors.
  • ORB-011 is a first-in-class modified interferon designed to act with a high level of precision on cDC1 dendritic immune cells, potent activators of tumor cell killing CD8+ T cells.
  • Preclinical research has shown that selective activation of cDC1s with such conditionally active interferon molecules translates into effective antitumor activity.
  • ORB-011 has the potential to harness the therapeutic activity of interferon in a new way,” said Nikolai Kley, Ph.D., Founder, President, and Chief Executive Officer of Orionis Biosciences.

NUS researchers develop an innovative and flexible method to study immune cell capabilities

Retrieved on: 
Monday, December 18, 2023

SINGAPORE, Dec. 17, 2023 /PRNewswire/ -- Our body's immune system is a complex network of organs, cells, and proteins that work in synchrony to protect our bodies against infections caused by pathogens and fight against disease-causing changes in our body, such as the emergence of cancer cells. Cell-mediated cytotoxicity is one of such defence mechanisms carried out by the immune system that fights against foreign cells.

Key Points: 
  • "The novel methodology proposed by my team is highly selective in identifying the killer cells capable of efficiently eliminating a target cell.
  • During cell-mediated cytotoxicity, some immune cells can destroy foreign cells through cell lysis by releasing proteins that trigger a cascade of cellular processes that destroy foreign cells.
  • The researchers named this new method PAINTKiller (for 'proximity affinity intracellular transfer identification of killer cells').
  • The NUS researchers used an intracellular staining dye known as carboxyfluorescein succinimidyl ester (CFSE) to stain the foreign cells.

BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE

Retrieved on: 
Monday, November 27, 2023

MINNEAPOLIS, Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST.

Key Points: 
  • MINNEAPOLIS, Nov. 27, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating Officer will present at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday, November 29, 2023, at 2:10 p.m. EST.
  • A live webcast of the presentation can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar .
  • These reagent and protein analysis solutions are sold to biomedical researchers as well as clinical research laboratories and constitute the Protein Sciences Segment.
  • With thousands of products in its portfolio, Bio-Techne generated approximately $1.1 billion in net sales in fiscal 2023 and has approximately 3,200 employees worldwide.

UCB Announces U.S. Availability of BIMZELX® for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Tuesday, November 14, 2023

BIMZELX was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.

Key Points: 
  • BIMZELX was approved by the U.S. Food and Drug Administration (FDA) on October 17, 2023.
  • "While the treatment landscape for psoriasis has evolved in recent years, many unmet needs remain for the more than 7.5 million adults in the U.S. living with the disease," said Dr. Jeffrey Stark, Head of Medical, U.S. Immunology, UCB.
  • "That's why we developed BIMZELX Navigate™, a tailored patient support program designed to help patients with access, affordability, and treatment support throughout their treatment journeys with BIMZELX."
  • Through BIMZELX Navigate, UCB offers tailored patient support to all those with moderate-to-severe plaque psoriasis upon receiving their BIMZELX prescription.